Ashesh Parikh, DO
Cardiovascular Disease · Plano, TXNPI 1003080375
Payments from drug & device makers
Across 275 payments — averaging $56.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Medtronic$927
- Boston Scientific$627
- Merck$603
- Novartis$562
- E.r. Squibb & Sons, L.L.C.$513
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$8,40054%
- Food & beverage$7,23346%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $9,042 |
| Medtronic(2 entities) | 9 | $927 |
| Boston Scientific | 5 | $627 |
| Merck | 32 | $603 |
| Novartis | 30 | $562 |
| E.r. Squibb & Sons, L.L.C. | 21 | $513 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $478 |
| Amgen | 17 | $352 |
| Heartflow, Inc. | 5 | $302 |
| Abbott | 6 | $295 |
| Johnson & Johnson | 16 | $290 |
| AstraZeneca | 8 | $261 |
| Astellas Pharma US Inc | 8 | $152 |
| Irhythm Technologies, Inc. | 3 | $139 |
| Boehringer Ingelheim | 8 | $138 |
| Edwards Lifesciences | 5 | $113 |
| Alnylam Pharmaceuticals Inc. | 4 | $95 |
| Kestra Medical Technology Services, Inc. | 3 | $90 |
| Novo Nordisk | 3 | $71 |
| Davol Inc. | 3 | $69 |
| Abiomed | 2 | $57 |
| Philips North America LLC | 2 | $57 |
| Cvrx, Inc. | 3 | $52 |
| Atricure, Inc. | 2 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Recor Medical Inc | 1 | $29 |
| BD | 1 | $26 |
| Itamar Medical Inc | 1 | $23 |
| Medicomp Inc | 1 | $21 |
| Bayer | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$8,400
- FFRct$243
- ONYX FRONTIER$226
- LINQ II$211
- SYMPLICITY G3$161
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$160
- GENERAL - STENTS$147
- Repatha$125
- CAMZYOS$121
- WATCHMAN Access System$119
- FARXIGA$118
- Varithena Administration Pack$110
- Rotablator Rotational Atherectomy System Console Kit$110
- CoreValve Evolut$109
- Micra$107
- LifeVest$100
How this compares
$15,633 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $399,635 |
| XareltoRivaroxaban | 105 | $114,807 |
| Repatha SureclickEvolocumab | 121 | $77,492 |
| EntrestoSacubitril/Valsartan | 22 | $38,718 |
| Praluent PenAlirocumab | 28 | $13,931 |
| Clonidine | 47 | $4,904 |
| Midodrine Hcl | 37 | $4,128 |
| Metoprolol Succinate | 288 | $3,439 |
| Nifedipine ErNifedipine | 98 | $3,325 |
| Losartan Potassium | 320 | $2,865 |
| Nebivolol Hcl | 35 | $2,799 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 11 | $2,507 |
| Ranolazine ErRanolazine | 33 | $2,411 |
| Amlodipine Besylate | 295 | $2,009 |
| Rosuvastatin Calcium | 155 | $1,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,042 | $399,635373 claims |
| Johnson & JohnsonXarelto | $290 | $114,807105 claims |
| NovartisEntresto | $562 | $38,71822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- David BrownPlano$2.7M
- Sahil BakshiPlano$628K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.